WILSON TROY EDWARD

Insider trading profile for Wilson Troy Edward across Kura Oncology (KURA, primary), Puma Biotech (PBYI), and Avidity Biosciences (RNA): KURA: 92 tx 2016-2026. Key events: 2025-11-13 A-code 182,500 shares (large RSU/option exercise); 2025-09-27 A-code 182,500 shares; 2025-09-08 P-code (open-market purchase) 50,000 shares at $8.20 -- meaningful discretionary buy; 2025-08-13 P-code 13,494 at $6.64; 2025-08-12 P-code 36,506 at $5.85. S-code sells: 2025-09-29 (36,615 at $8.94). M-code vesting: 2026-03-23 (6,103 x 2 at $6.15). Net KURA: 100K acquired vs 699K sold historically, but recent window shows significant P-code buying + A-code exercises. PBYI: 2026-06-11 A-code 27,000 shares; 2026-06-12 S-code 10,800 at $7.20 (partial liquidation of exercised shares). RNA: 30 tx 2020-2025. M-code 14.5K batches at $12.48 exercise + S-code sells at $45 (2025-08/09). 2025-06-13 PBYI S-code 10,800 at $3.40. KEY SIGNAL: The KURA P-code buys (50K at $8.20 + 13.5K at $6.64 + 36.5K at $5.85 = 100K total open-market purchases at $5.85-$8.20) are the most significant bullish signal in this profile. This is an insider putting NEW MONEY to work in KURA at what appears to be near 52-week lows ($5.85-$8.20 range). The A-code exercises (182.5K x 2 = 365K shares) represent institutional-grade option exercises being held. The combination of $100K+ in open-market buys PLUS 365K in exercised shares being retained suggests meaningful conviction in KURA. The PBYI activity shows standard exercise-and-partial-liquidate pattern. The RNA sells at $45 (from $12.48 exercise) represent 3.6x profit-taking. Mixed read: bullish on KURA specifically (large open-market buys at weakness + big exercised position held); bearish on RNA (profit-taking at 3.6x); PBYI neutral. The KURA profile is one of the more constructive seen in this batch despite the historical net-sell.